1.Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
Tomonori NUKARIYA ; Toshiki TEZUKA ; Shohei OKUSA ; Ryotaro OKOCHI ; Yuto SAKAI ; Yoshihiro NIHEI ; Jin NAKAHARA ; Morinobu SEKI
Journal of Movement Disorders 2025;18(2):179-181
2.Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
Tomonori NUKARIYA ; Toshiki TEZUKA ; Shohei OKUSA ; Ryotaro OKOCHI ; Yuto SAKAI ; Yoshihiro NIHEI ; Jin NAKAHARA ; Morinobu SEKI
Journal of Movement Disorders 2025;18(2):179-181
3.Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
Tomonori NUKARIYA ; Toshiki TEZUKA ; Shohei OKUSA ; Ryotaro OKOCHI ; Yuto SAKAI ; Yoshihiro NIHEI ; Jin NAKAHARA ; Morinobu SEKI
Journal of Movement Disorders 2025;18(2):179-181
4.Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
Toshiki TEZUKA ; Tomonori NUKARIYA ; Yuta KIZUKA ; Shohei OKUSA ; Ryotaro OKOCHI ; Yuto SAKAI ; Yoshihiro NIHEI ; Jin NAKAHARA ; Morinobu SEKI
Journal of Movement Disorders 2024;17(4):453-455